Information Provided By: 
Fly News Breaks for October 11, 2019
QURE
Oct 11, 2019 | 05:08 EDT
Stifel analyst Paul Matteis initiated coverage of uniQure with a Buy rating and $79 price target. The company's AMT-061 is well positioned, and "mostly derisked," as a potentially first/best-in-class hemophilia B gene therapy, Matteis tells investors in a research note. The analyst also views uniQure as an emerging platform company, with a leadership position in gene therapy manufacturing.
News For QURE From the Last 2 Days
There are no results for your query QURE
